UArizona Health Sciences Study Shows SARS-CoV-2 Antibodies Provide Lasting Immunity


TUCSON, Ariz. – One of the most significant questions about the novel coronavirus is whether people who are infected are immune from reinfection and, if so, for how long. 

To determine the answer, University of Arizona Health Sciences researchers studied the production of antibodies from a sample of nearly 6,000 people and found immunity persists for at least several months after being infected with SARS-CoV-2, the virus that causes COVID-19.

Janko Nikolich-Žugich, MD, PhD, is internationally recognized as a leading immunologist and gerontologist. (Photo: University of Arizona Health Sciences, Kris Hanning)

“We clearly see high-quality antibodies still being produced five to seven months after SARS-CoV-2 infection,” said Deepta Bhattacharya, PhD, associate professor, UArizona College of Medicine – Tucson, Department of Immunobiology. “Many concerns have been expressed about immunity against COVID-19 not lasting. We used this study to investigate that question and found immunity is stable for at least five months.”

The resulting paper, “Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low Prevalence Communities and Reveal Durable Humoral Immunity,” was published today in the journal Immunity. Dr. Bhattacharya and Janko Nikolich-Žugich, MD, PhD, professor and head of the Department of Immunobiology, led the research team.

See a video about how UArizona Health Sciences researchers are seeking to unlock the immune response to COVID-19 to save lives. 

When a virus first infects cells, the immune system deploys short-lived plasma cells that produce antibodies to immediately fight the virus. Those antibodies appear in blood tests within 14 days of infection.

Deepta Bhattacharya, PhD, gets blood drawn for the antibody test he helped develop. (Photo: University of Arizona Health Sciences, Kris Hanning)

The second stage of the immune response is the creation of long-lived plasma cells, which produce high-quality antibodies that provide lasting immunity. Drs. Bhattacharya and Nikolich-Žugich tracked antibody levels over several months in people who tested positive for SARS-CoV-2 antibodies. They found SARS-CoV-2 antibodies are present in blood tests at viable levels for at least five to seven months, although they believe immunity lasts much longer.   

“Whether antibodies provide lasting protection against SARS-CoV-2 has been one of the most difficult questions to answer,” said UArizona Health Sciences Senior Vice President Michael D. Dake, MD, who is a co-author on the paper. “This research not only has given us the ability to accurately test for antibodies against COVID-19, but also has armed us with the knowledge that lasting immunity is a reality.”

Earlier studies extrapolated antibody production from initial infections and suggested antibody levels drop quickly after infection, providing only short-term immunity. Dr. Bhattacharya believes those conclusions focused on short-lived plasma cells and failed to take into account long-lived plasma cells and the high-affinity antibodies they produce.

(left to right) Jennifer Uhrlaub and Rachel Wong perform assays in Dr. Nikolich-Žugich’s lab.

“The latest time-points we tracked in infected individuals were past seven months, so that is the longest period of time we can confirm immunity lasts,” Dr. Bhattacharya said. “That said, we know that people who were infected with the first SARS coronavirus, which is the most similar virus to SARS-CoV-2, are still seeing immunity 17 years after infection. If SARS-CoV-2 is anything like the first one, we expect antibodies to last at least two years, and it would be unlikely for anything much shorter.”

The study began when Drs. Nikolich-Žugich and Bhattacharya, both members of the UArizona BIO5 Institute, led a UArizona Health Sciences team that developed a blood test to check for SARS-CoV-2 antibodies. A partnership with the state led to 5,882 volunteers undergoing antibody testing in Pima County, Ariz., starting April 30. The testing efforts later were expanded statewide.

Since antibodies attach to viruses at more than one location, the UArizona Health Sciences test was developed employing two different parts of the SARS-CoV-2 virus – S1 and S2. Most tests look for antibodies at S1, which includes the receptor-binding domain wherein the spike protein binds to a protein receptor to infect cells. The UArizona Health Sciences test also analyzes the S2 region of the spike protein. Antibodies must be present in both locations for the test to be determined positive.

Assays were developed to test for the presence and levels of neutralizing antibodies in blood samples.

“When we began, the first test we developed was 99% accurate for measuring antibodies in one part of the virus,” Dr. Nikolich-Žugich said. “We decided to confirm, and hopefully improve, that accuracy level by looking at another part of the virus that makes antibodies independent of the first location. We then validated that test, knowing some people will make antibodies more consistently for one part of the virus than the other. We put the two tests together, and only people who show antibody production for both parts of the test are determined to be positive.”  

The scientific verification of the high level of accuracy of the UArizona Health Sciences antibody test is the other finding highlighted in the Immunity paper. Of 5,882 tests completed, only one returned a false positive, a rate of less than .02%. The test received U.S. Food and Drug Administration emergency use authorization in August.

Dr. Nikolich-Žugich said the team now has tested almost 30,000 people. Antibody tests still are available for anyone in Arizona age 18 and older at multiple locations throughout the state. Visit for more information and to sign up for testing.

Funding was provided in part by U.S. Public Health Service Award Nos. AG020719 and AG057701; U.S. Centers for Disease Control and Prevention Award No. 75D30120C08379; the state of Arizona Contract No. CTR050053; National Institutes of Allergy and Infectious Diseases, a unit of the National Institutes of Health, Award Nos. R01AI099108 and R01AI129945; and the Bowman Endowment in Medical Sciences.

More information on the College of Medicine – Tucson’s activities regarding the COVID-19 pandemic is at this link.
The UArizona Health Sciences COVID-19 Research webpage can be found here.

For the latest on the University of Arizona response to the novel coronavirus, visit the university's COVID-19 webpage.

For UANews coverage of COVID-19, visit

# # #

Another version of this article appeared originally on the Tomorrow Is Here webpage of the UArizona Health Sciences website.

NOTE TO EDITORS/WRITERS: Photos and video available here –

About the University of Arizona College of Medicine – Tucson
The University of Arizona College of Medicine – Tucson is shaping the future of medicine through state-of-the-art medical education programs, groundbreaking research and advancements in patient care in Arizona and beyond. Founded in 1967, the college boasts more than 50 years of innovation, ranking among the top medical schools in the nation for research and primary care. Through the university's partnership with Banner Health, one of the largest nonprofit health care systems in the country, the college is leading the way in academic medicine. For more information, visit (Follow us: Facebook | Twitter | Instagram | LinkedIn).

About the University of Arizona Health Sciences
The University of Arizona Health Sciences is the statewide leader in biomedical research and health professions training. UArizona Health Sciences includes the Colleges of Medicine (Tucson and Phoenix), Nursing, Pharmacy, and the Mel and Enid Zuckerman College of Public Health, with main campus locations in Tucson and the Phoenix Biomedical Campus in downtown Phoenix. From these vantage points, Health Sciences reaches across the state of Arizona, the greater Southwest and around the world to provide next-generation education, research and outreach. A major economic engine, Health Sciences employs nearly 5,000 people, has approximately 4,000 students and 900 faculty members, and garners $200 million in research grants and contracts annually. For more information: (Follow us: Facebook | Twitter | YouTube | LinkedIn | Instagram).

Release Date: 
10/09/2020 - 5:25am
Original Story: